Organon OGN Clarinex — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Organon in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Organon's clarinex — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Organon's clarinex — revenue?
- Organon (OGN) reported clarinex — revenue of $31M in Q1 2026.
- How has Organon's clarinex — revenue changed year-over-year?
- Organon's clarinex — revenue decreased by 8.8% year-over-year, from $34M to $31M.
- What is the long-term trend for Organon's clarinex — revenue?
- Over 4 years (2021 to 2025), Organon's clarinex — revenue has grown at a 2.6% compound annual growth rate (CAGR), from $111M to $123M.
- What does clarinex — revenue mean?
- This metric represents the total gross sales generated from the Clarinex product line, a key component of the company's established medicines portfolio. It reflects the market demand and commercial performance of this specific pharmaceutical therapy over a defined fiscal period. Monitoring this revenue stream helps investors assess the lifecycle maturity and contribution of legacy assets to the company's overall top-line results.